S-1: Picard Medical Files for Resale of Shares

Picard Medical, Inc. has filed a registration statement for the resale of up to 16,211,479 shares of its Common Stock by selling stockholders.

Summary

• Picard Medical, Inc. (PMI) has filed an S-1 registration statement to allow selling stockholders to resell up to 16,211,479 shares of its Common Stock.
• These shares include those issuable upon exercise of Placement Agent Warrants, QC Origination Shares, and Sindex Shares.
• The company will not receive proceeds from the sale of these shares by selling stockholders, but may receive proceeds from warrant exercises.
• PMI's core business is through its subsidiary SynCardia, which manufactures and sells the SynCardia Total Artificial Heart (TAH).
• The company has a history of significant losses and expects to continue incurring losses.
• PMI is also developing the next-generation Emperor TAH and working on expanding the indications for its current TAH product.
• The company received a NYSE notice of noncompliance regarding stockholder equity and net losses, and is preparing a plan to regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the company's continued net losses, increased operating expenses, and the NYSE non-compliance notice, despite progress in product development and financing activities.

Positives

• The SynCardia TAH is the only total artificial heart approved for commercial use in the United States and Canada.
• Over 2,100 SynCardia TAHs have been implanted globally.
• Implantation procedures are covered by CMS under National Coverage Determination 20.9.1 and generally reimbursed under DRG 001.
• The company is actively developing next-generation technology (Emperor TAH) and seeking expanded indications for its current product.
• The company has a history of securing financing, including an IPO in September 2025 and a $15 million Senior Secured Note issuance in December 2025.

Negatives

• The company has a history of significant losses and expects to continue incurring losses for the foreseeable future.
• The company has a history of net losses and a working capital deficiency, raising substantial doubt about its ability to continue as a going concern.
• PMI received a NYSE notice of noncompliance regarding stockholder equity and net losses, and faces potential delisting if it cannot regain compliance.
• The company relies on a limited number of products for revenue, making it vulnerable to declines in sales or market acceptance.
• Manufacturing relies on specialized suppliers, with no second-source suppliers for many critical components.
• The company faces significant customer concentrations, with a small number of customers accounting for a substantial portion of revenues.
• The company is subject to extensive government regulation, which can be costly and time-consuming.
• The company has prior weaknesses in its CE MDD regulatory regime and is migrating to CE MDR, with potential adverse effects if not successful.
• Many aspects of the SynCardia TAH are no longer protected by patents.
• The company has outstanding royalty payments to Medtronic and a security interest granted to Medtronic related to a license agreement.

Risks

• The company has a history of significant losses and expects to continue incurring losses, potentially impacting its ability to continue as a going concern.
• Sales of substantial amounts of Common Stock by selling stockholders could cause the market price to decline.
• The exercise of warrants and conversion of convertible notes will result in dilution to existing stockholders.
• The company is subject to extensive government regulation, which could make it more expensive and time-consuming to introduce new or improved products.
• The company's manufacturing operations, R&D activities, and corporate headquarters are based at a single location, posing risks in case of disruption.
• Failure to protect its information technology infrastructure against cyber-based attacks could significantly disrupt operations.
• Failure to protect the product and patient from cybersecurity risks associated with device usage could endanger patient safety.
• The demand for total artificial hearts depends on medical advances that could provide better alternatives.
• The company is no longer a controlled company and may not be able to comply with continued listing standards of the NYSE.
• The company's ability to use net operating loss carryforwards may be subject to limitations.
• The company may be subject to claims that employees have inadvertently or intentionally used or disclosed trade secrets or proprietary information of former employers.
• The company's share price may be volatile, and purchasers could incur substantial losses.
• The company's independent registered public accounting firm included an explanatory paragraph relating to its ability to continue as a going concern in its report.
• The company does not intend to pay cash dividends for the foreseeable future.
• Future issuances of Common Stock could cause the market price to decline.
• The exercise of outstanding warrants and stock options may adversely affect the trading price of securities.
• The company continues to incur increased costs and become subject to additional regulations as a public company.
• The company is an emerging growth company and a smaller reporting company, which may make its securities less attractive to investors.
• The company could be subject to securities class action or derivative litigation.
• If the company is unable to implement and maintain effective internal control over financial reporting, investors may lose confidence.
• An active trading market for the company's securities may not develop or be sustained.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, the company's stock price and trading volume could decline.
• The company's charter designates specific courts as the exclusive forum for substantially all stockholder litigation matters, which could limit stockholders' ability to obtain a favorable forum.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the foreseeable future due to scaling operations, investing in new device development, and the costs associated with being a public company. Future capital needs are expected to be met through a combination of equity and debt financing.

Management Comments

• PMI functions as a holding company and owns 100% of the membership interests of SynCardia. Business operations are carried out by and through SynCardia, and accordingly most of the information in this prospectus pertains to SynCardia's business.
• SynCardia is a medical technology company that manufactures and sells the only U.S. Food and Drug Administration (FDA) and Health Canada approved Total Artificial Heart (TAH), which fully replaces the function of a failing human heart.
• PMI's strategy focuses on expanding the clinical use of the SynCardia Total Artificial Heart, developing next generation technologies, improving manufacturing efficiency, and pursuing selected international regulatory approvals.

Industry Context

StockSavvy.ai notes that Picard Medical operates in the highly competitive and regulated medical device sector, specifically focusing on advanced heart failure solutions. The company's primary product, the SynCardia TAH, faces competition from other mechanical circulatory support devices like LVADs, as well as emerging TAH technologies from companies like CARMAT SA and BiVACOR Inc. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory approval processes.

Comparison to Industry Standards

• The SynCardia TAH is the only total artificial heart approved for commercial use in the United States and Canada, distinguishing it from competitors like CARMAT SA (Aeson TAH, CE Mark in EU) and BiVACOR Inc. (early-stage human clinical testing).
• PMI has over 2,100 SynCardia TAH implants globally, a significant volume compared to CARMAT's reported 108 implants as of March 2026.
• The SynCardia TAH implant weight (200-240g) is considerably lighter than CARMAT's Aeson TAH (900g), potentially offering a size advantage for certain patient demographics.
• PMI's manufacturing processes are ISO 13485-certified, meeting regulatory standards for medical devices, which is a critical benchmark in the industry.

Corporate Governance

Legal Proceedings

• A putative securities class action lawsuit (Louie v. Picard Medical, Inc., et al.) was filed in February 2026, alleging violations of federal securities laws in connection with the company's IPO and subsequent disclosures. PMI believes the claims are without merit and intends to defend vigorously.

Related Party Transactions

• PMI has engaged in numerous loan transactions with entities affiliated with its executive directors, primarily Fang Family Fund, LLC and Fang Family Fund II, LLC, totaling millions of dollars.
• These loans have carried various interest rates and repayment terms, with some being interest-free and others consolidated into convertible notes.
• Richard Fang, a director, donated a $7.0 million convertible note to not-for-profit organizations, Nexus Science Foundation Inc. and Another Dimension Foundation.
• The company has a related party note receivable from Versa Capital Management, LLC, which was determined to be uncollectible and written off in December 2025.

Stakeholder Impact

• Shareholders may experience dilution due to the exercise of outstanding warrants and stock options, and potential future equity issuances.
• The company's ability to continue as a going concern raises concerns for all stakeholders, including investors, employees, and creditors.
• Potential delisting from the NYSE could significantly reduce liquidity for shareholders and impact the company's ability to raise future capital.
• The company's reliance on key suppliers could impact product availability and operations, affecting customers and potentially patients.
• The company's ongoing R&D and regulatory efforts are crucial for future growth, impacting the long-term value for shareholders.

Next Steps

• PMI is working with the FDA to expand the approved indications for use of the SynCardia TAH beyond the current BTT indication, including seeking approval for bridge to candidacy (BTC) and longer duration support.
• The company is pursuing CE Mark certification in the European Union under the Medical Device Regulation (MDR) framework.
• PMI is evaluating opportunities to improve manufacturing efficiency and reduce production costs.
• The company is developing next-generation pneumatic driver technology, including the Unicorn driver.
• PMI expects to submit a 180-day PMA supplement to the FDA in Q3 2026 for revisions to the SynCardia TAH indications for use.
• The company expects to complete regulatory testing for the Unicorn driver in the second half of 2026.
• PMI expects FDA approval for the upgraded Freedom+ Driver by the end of 2026.
• The company expects to gain FDA approvals for next-generation Freedom and C2 Drivers during Q2 2026 and Q2 2028, respectively.
• The company expects to receive initial feedback on its China NMPA application during 2026, with potential approval within 18 months of filing.

Key Dates

Recommendation

While Picard Medical is a pioneer in the total artificial heart market with significant regulatory approvals and a developing pipeline, the company's ongoing substantial losses, going concern issues, and NYSE non-compliance notice present considerable risks. The potential for dilution from warrant exercises and the competitive landscape also warrant caution. Therefore, a 'hold' recommendation is appropriate, pending clearer signs of financial stability and successful commercial scaling.

Keywords

Picard Medical, S-1 Filing, Common Stock, Warrants, Resale, Medical Device, Total Artificial Heart, SynCardia TAH, SEC Filing, IPO, Financing